Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy

Apatsara Treenert¹, Nutthada Areepium¹*, Suebpong Tanasanvimon²

Abstract

Purpose: Irinotecan is an anticancer medicine which is used mostly in metastatic colorectal cancer (mCRC) treatment as second or third line chemotherapy. Several factors affect its efficacy and toxicity, including pharmacogenomics. This study aimed to investigate the impacts of ABCC2 and SLCO1B1 polymorphisms on treatment responses in irinotecan-based chemotherapy in 49 Thai mCRC patients. Materials and Methods: Forty-nine participants with mCRC enrolled in this study received irinotecan-based chemotherapy from January to June 2017. Genotypic analyses of ABCC2 (C>T, rs717620) and SLCO1B1 (A>G, rs2306283) were performed. Treatment responses were evaluated after at least three cycles of chemotherapy were given. Results: Allele frequencies of ABCC2 (C>T) and SLCO1B1 (A>G) were found at 18.37% and 78.57%, respectively. Neither was associated with treatment responses. However, combined genotypes of ABCC2 and SLCO1B1 tended to be associated with clinical benefits in terms of partial responses (PR) and stable disease (SD). All patients (100%) with at least one variant allele of SLCO1B1 and ABCC2 were in a PR or SD group, while patients with other genotypes had progressive disease (PD) at 45.5% to 70%, (p = 0.059). Conclusion: The combined effect of ABCC2 and SLCO1B1 polymorphisms tended to be associated with treatment responses in irinotecan-based treated mCRC patients. Therefore, such polymorphisms could be factors impacting inter-individual variation of irinotecan efficacy in Thai mCRC patients.

Keywords: Metastatic colorectal cancer - ABCC2 - SLCO1B1 - irinotecan

Introduction

Colorectal cancer (CRC) represents as one of the most prevalent and deadly tumor types with worldwide mortality rates continuing to rise. The World Health Organization (WHO) reported the incidence of CRC cases at approximately 1.36 million new cases and 0.69 million deaths in 2012 (Hashim et al., 2016). In Thailand, the crude rate of CRC was 9 per 100,000 in males and 7 per 100,000 in females. Half of these patients presented with advanced stage CRC (28.9% with TNM stage 3 and 38.8% TNM stage 4, respectively). Nearly 90% of patients diagnosed early who receive optimized therapy can be expected to survive 5 years while the overall survival rate of metastatic colorectal cancer (mCRC) patients is only 5% (Phiphatpatthamaanphaphan and Vilaichone, 2016).

Chemotherapy is the main treatment for mCRC (Benson et al., 2017). Irinotecan is an anticancer drug that inhibits topoisomerase I, which is approved for mCRC treatment in combination with 5-fluorouracil and folinic acid in a first line treatment setting or as a monotherapy in the second line setting. The overall response rate of irinotecan-based regimens was from 30-50% (Colucci et al., 2005; Tounigand et al., 2004). However, severe adverse events such as diarrhea (20%) and neutropenia (34%) lead to dose reduction, early cessation of treatment, or death (Fuchs et al., 2003). The severity of these adverse events is related to a high concentration of 7-ethyl-10-hydroxycamptothecin or SN-38, the active metabolite of irinotecan. SN-38 is conjugated with glucuronic acid by hepatic extra hepatic Uridine 5’-diphosphate-glucuronosyltransferase (UDP-glucuronosyltransferase or UGT), changing SN-38 to SN-38G, the inactive metabolite of irinotecan. Therefore, the efficiency of SN-38 glucuronidation and transport relies heavily on UGT1A enzymes and drug transport activity.

Many studies have been conducted to explain predictive factors for adverse events in irinotecan chemotherapy. One very well-known factor is genetic polymorphisms of UGT, a phase II drug metabolizing enzyme involved in SN-38 detoxification which is associated with differences

¹Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, ²Department of Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. *For Correspondence: Nutthada.A@pharm.chula.ac.th
in toxicity from irinotecan-based treatment regimens. In irinotecan pharmacogenomic studies, it is observed that Caucasian patients carrying the UGT1A1*28 allele are at increased risk of severe neutropenia (Liu et al., 2014). The other variant UGT1A1*6 (211G>A, rs4148323) which is commonly found in East Asians while rarely detected in Caucasians and Africans is also associated with reduced UGT1A enzyme function (Minami et al., 2007).

The regulatory status and other issues around irinotecan therapy are based on cumulative evidence of the association of UGT1A1 genotypes with severe toxicity, especially neutropenia, which has led to the clinical use of a diagnostic kit for the UGT1A1*28 allele in the US (August, 2005). Subsequently, the same practice was considered for the clinical use of a diagnostic kit for UGT1A1*28 and *6 alleles in Japan (March, 2009).

Although variability in irinotecan pharmacokinetics and pharmacodynamics has been partially described for UGT1A variants, allele frequencies of UGT1A1*28 and UGT1A1*6 still slightly detected in Thai mCRC were 12.5% and 8%, respectively, they do not fully explain the reason for the subgroups of non-carrier patients who may experience irinotecan-induced toxicity and non-responders to treatment (Atasilp et al., 2016).

In addition to the UGT family, many other enzymes are involved in irinotecan metabolism. The ATP-binding cassette (ABC) and solute-carrier (SLC) family of transporters can also modulate irinotecan pharmacokinetic and pharmacodynamic effects. Irinotecan, SN-38 and SN-38G are transported out of the cell into bile by members of the ABC transporter family especially ABCC2, while SLCO1B1 is a major influx transporter. SLCO1B1 is associated with the uptake of SN-38 from the blood to be transported to the liver (Haenisch et al., 2007). Therefore, genetic variations of ABCC2 and SLCO1B1 are suspected of influencing inter-individual variability which could impact treatment responses to irinotecan-based chemotherapy.

In Asians, allele frequency T of ABCC2 detected at a high allele frequency (approximately 20%) in advanced colorectal cancer (Fujita et al., 2008). Previous studies have demonstrated that ABCC2 polymorphism was associated with the specific pharmacokinetics of SN-38, which may account for overall irinotecan treatment response rates. Almost 20% of mRNA showed reduced activity in whom with ABCC2 variant gene in kidney cortex tissue of nephrectomized renal cell cancer patients (Haenisch et al., 2007). ABCC2 polymorphism was statistically significant with increased SN-38 exposure in terms of the area under the curve of time and concentration (Akiyama et al., 2012). However, several recently published studies have provided conflicting data. Metastatic colorectal cancer patients without ABCC2 (rs717620, C>T) had increased overall response rate and median progression-free survival (PFS) (P = 0.031) (Fujita et al., 2008). In contrast, in a study of Singaporean nasopharyngeal carcinoma patients, ABCC2 polymorphism resulted in a reduced irinotecan plasma concentration time curve (AUC) compared with the CC genotype (Zhou et al., 2005).

The allele frequency G of SLCO1B1*1b is also high in Asians (about 64.7-75%) (Fujita et al., 2008; Huang et al., 2013). The SLCO1B1*1b polymorphism was associated with increased enzyme function, leading to increased hepatic uptake of SN-38 from plasma to human (Nozawa et al., 2005). A previous study stated that the SLCO1B1 rs2306283 polymorphism significantly increased tumor response and presented a rapid response rate in patients with the GA/AA genotype. The response rate of these patients was higher than in patients with the homozygous wild genotype (G/G) (odds ratio [OR] =3.583, 95% CI=1.301-9.871, P = 0.011). Furthermore, the GA/AA genotype was associated with a better PFS (hazard ratio =0.402, 95% CI = 0.171-0.945, P = 0.037) (Teft et al., 2015). This finding contrasts with another study which found significantly increased PFS in patients with the G/G genotype when compared with patients carrying at least one wild-type allele (HR=1.60, 95% CI=1.04-2.46) (Teft et al., 2015).

At present, no studies have explored the association between ABCC2 and SLCO1B1*1b polymorphisms on treatment response in Thais with CRC. Therefore, the aim of the present research was to investigate the impacts of ABCC2 and SLCO1B1 polymorphisms on treatment responses to irinotecan-based chemotherapy in Thai mCRC patients.

Materials and Methods

Patients and Data Collection

Forty-nine patients with mCRC were enrolled in this prospective cohort study. All participants received irinotecan-based chemotherapy from January to June 2017 at the outpatient oncology department of King Chulalongkorn Memorial Hospital (KCMH) in Bangkok, Thailand. The inclusion criteria were: patients with mCRC confirmed by histopathology or cytology; over 18 years of age; an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; scheduled to receive irinotecan-based chemotherapy of at least 3 cycles. The study protocol was approved by the Institutional Review Board of the Faculty of Medicine at Chulalongkorn University, Bangkok, Thailand (IRB number 699/59). All patients signed an informed consent document which is in accordance with ethical standards laid down in the 1964 Declaration of Helsinki.

Demographic and other relevant clinical data were collected from patient medical records. 5 ml of peripheral blood was collected from each subject by a professional nurse and stored in EDTA tubes. Genomic DNA was extracted from blood samples using a QIAIamp blood kit (QIAGEN GmbH, Hilden, Germany). Analysis of the ABCC2 (C>T), rs717620 and SLCO1B1*1b (388A>G), and rs2306283 genotypes was performed using real-time polymerase chain reaction restriction (qPCR) with Taqman genotyping assay. After PCR amplification, endpoint plates were read on a StepOnePlus Real time PCR System (Applied Biosystem Inc., Foster City, CA USA). Using fluorescence measurements made during plate readings, the SDS software plots Rnvalues based on the fluorescence signals from each well then determines which alleles were in each sample.
Treatment response was an objective tumor response which was classified according to Response Evaluation Criteria in Solid tumors (RECIST) criteria, version 1. Treatment response was evaluated after completing at least 3 cycles. A responder was a patient who had a partial response (PR) or complete response (CR) and other patients who had progressive disease (PD) or stable disease (SD) were classified as non-responders. Nonetheless, patients with PR or CR or SD were considered as groups with clinical benefit.

Irinotecan-based chemotherapy regimens given in this study, following physician recommendations, were:

**Single irinotecan regimen**
- 125 or 300mg/m², 90 minute intravenous irinotecan infusion on day 1;

**Irinotecan plus capecitabine regimen**
- 125-300mg/m², 90 minute irinotecan intravenous infusion on day 1; 2,000 mg/m² of capecitabine from day 1-14;

**IFL regimen**
- 125-150 mg/m², 90 minute intravenous irinotecan infusion on day 1; 20 mg/m² intravenous leucovorin (LV) infusion on day 1; 500 mg/m² intravenous fluorouracil as a bolus on day 1 repeated every 2 weeks;

**Irinotecan+other**
- 5 mg/kg intravenous bevacizumab infusion once every 2 weeks; 125 mg/m², 90 minute intravenous irinotecan infusion on day 1; 20 mg/m² intravenous leucovorin infusion on day 1; 500 mg/m² intravenous fluorouracil as a bolus on day 1 repeated every 2 weeks; or Cetuximab 400 mg/m² intravenous infusion on day 1; 125 mg/m², 90 min intravenous irinotecan Infusion on day 1; 20 mg/m² intravenous leucovorin infusion on day 1; 500 mg/m² intravenous fluorouracil as a bolus on day 1 repeated every 2 weeks.

**Statistical Analysis**
Baseline characteristics of demographic data are shown as means ± standard deviation (SD) for continuous variables and number of participants (%) for category variables. The association between ABCC2 and SLCO1B1 polymorphisms on treatment response were analyzed by Chi-squared test or Fisher’s exact test. Statistical tests provided two sides. The p value < 0.05 was considered statistically significant. Statistical analysis was performed with SPSS version 22.0 (SPSS. Co., Ltd., Bangkok, Thailand).

**Results**

**Patient Characteristics**
Forty-nine participants were included in this study. Patient characteristics are shown in Table 1. Thirty-two (65.3%) participants were male and 17 (34.7%) were female. The average age was 59.6 ± 12.2 years. Adenocarcinoma with moderated differentiated histology was the most common cancer found in 21 patients.

**Table 1. Patient Characteristics and Treatment Response**

| Characteristic | N (%) |
|----------------|-------|
| Total number of participants | 49 |
| Age(mean ± SD) | 59.57±12.23 (26,81) |
| Gender | N % |
| Male | 32 65.3 |
| Female | 17 34.7 |
| Performances status | |
| ECOG score=0 | 4 8.2 |
| ECOG score=1 | 45 91.8 |
| Histology | |
| well differentiated | 19 38.8 |
| moderately differentiated | 21 42.9 |
| poorly differentiated | 6 12.2 |
| No data | 3 6.1 |
| Primary tumor site | |
| Colon | 18 36.7 |
| Sigmoid | 15 30.6 |
| Rectum | 16 32.7 |
| Metastatic site | |
| Liver | 10 20.4 |
| Lung | 6 12.2 |
| other (eg. peritoneal, pelvic, bladder, ovarian, spleen, ovary, bone) | 8 16.3 |
| lung and liver | 14 28.6 |
| liver or lung+other | 11 22.4 |
| Treatment line | |
| first line | 7 14.3 |
| Second line | 32 65.3 |
| >second line | 10 20.4 |
| Treatment regimen | |
| Irinotecan | 5 10.2 |
| Irinotecan+capecitabine | 9 18.4 |
| IFL | 31 63.3 |
| Irinotecan+other | 4 8.2 |
| Irinotecan dose | |
| 100-125 mg/m² | 25 51 |
| 150 mg/m² | 21 42.9 |
| 180 mg/m² | 3 6.1 |
| ABCC2 genotype | |
| C/C | 32 65.3 |
| C/T | 16 32.7 |
| T/T | 1 2.0 |
| SLCO1B1 genotype | |
| A/A | 5 10.2 |
| A/G | 11 22.4 |
| G/G | 33 67.3 |
| Responder | |
| Complete response (CR) | 0 0 |
| Partial response (PR) | 5 10.2 |
| Non-responder | |
| Stable disease (SD) | 22 44.9 |
| Progressive disease (PD) | 22 44.9 |

ECOG, Eastern Cooperative Oncology Group.
### Table 2. Association between Factors and Overall Response

| Factor                   | N   | Overall response* | χ² value | P-value |
|--------------------------|-----|-------------------|----------|---------|
|                          |     | PR (%)            | SD + PD (%) |         |
| Gender                   |     |                   |           |         |
| Male                     | 32  | 3 (9.4)           | 29 (90.6) | 0.069   | 1.000  |
| Female                   | 17  | 2 (11.8)          | 15 (88.2) | 0.668   | 0.639  |
| Age (years)              |     |                   |           |         |
| ≤ 60 years               | 28  | 2 (7.1)           | 26 (92.6) | 0.069   | 1.000  |
| > 60 years               | 21  | 3 (14.3)          | 18 (85.7) | 0.069   | 1.000  |
| ECOG status              |     |                   |           |         |
| 0                        | 4   | 1 (25)            | 3 (75)    | 1.041   | 0.359  |
| 1                        | 45  | 4 (8.9)           | 41 (91.1) | 0.069   | 1.000  |
| Histology                |     |                   |           |         |
| Well differentiated      | 19  | 3 (15.8)          | 16 (84.2) | 3.759   | 0.289  |
| Moderately differentiated| 21  | 1 (4.8)           | 20 (95.2) | 0.069   | 1.000  |
| Poorly differentiated    | 6   | 0 (0)             | 6 (100)   | 0.069   | 1.000  |
| No data                  | 3   | 1 (33.3)          | 2 (66.7)  | 0.069   | 1.000  |
| Primary tumor site       |     |                   |           |         |
| colon                    | 18  | 1 (5.6)           | 17 (94.4) | 0.069   | 1.000  |
| sigmoid                  | 15  | 2 (13.3)          | 13 (86.7) | 0.069   | 1.000  |
| rectum                   | 16  | 2 (12.5)          | 14 (87.5) | 0.069   | 1.000  |
| Metastatic site          |     |                   |           |         |
| liver                    | 10  | 2 (20)            | 8 (80)    | 0.069   | 1.000  |
| lung                     | 6   | 0 (0)             | 6 (100)   | 0.069   | 1.000  |
| other (eg. peritoneal, pelvic, bladder, ovarian, spleen, ovary, bone) | 8 | 0 (0)            | 8 (100)   | 0.069   | 1.000  |
| lung and liver           | 14  | 3 (21.4)          | 11 (78.6) | 0.069   | 1.000  |
| liver or lung+other      | 11  | 0 (0)             | 11 (100)  | 0.069   | 1.000  |
| Treatment line           |     |                   |           |         |
| first line               | 7   | 2 (28.6)          | 5 (71.4)  | 0.069   | 1.000  |
| second line              | 32  | 2 (6.3)           | 30 (93.7) | 0.069   | 1.000  |
| > second line            | 10  | 1 (10)            | 9 (90)    | 0.069   | 1.000  |
| Number of metastatic sites |     |                   |           |         |
| 1                        | 19  | 2 (10.5)          | 17 (89.5) | 0.069   | 1.000  |
| 2                        | 19  | 3 (15.8)          | 16 (84.2) | 0.069   | 1.000  |
| > 2                      | 11  | 0 (0)             | 11 (100)  | 0.069   | 1.000  |
| Previous treatment       |     |                   |           |         |
| Chemotherapy             | 4   | 1 (25)            | 3 (75)    | 0.069   | 1.000  |
| Surgery+chemotherapy     | 30  | 3 (10)            | 27 (90)   | 0.069   | 1.000  |
| Surgery+radiotherapy+chemotherapy | 11 | 1 (9.1)        | 10 (90.9) | 0.069   | 1.000  |
| Radiotherapy+chemotherapy| 4   | 0 (0)             | 4 (100)   | 0.069   | 1.000  |
| Treatment regimen        |     |                   |           |         |
| Irinotecan               | 5   | 0 (0)             | 5 (100)   | 0.069   | 1.000  |
| Irinotecan+capecitabine  | 9   | 2 (22.2)          | 7 (77.8)  | 0.069   | 1.000  |
| IFL                      | 31  | 1 (3.2)           | 30 (96.8) | 0.069   | 1.000  |
| Irinotecan+other         | 4   | 2 (50)            | 2 (50)    | 0.069   | 1.000  |
| Irinotecan dose          |     |                   |           |         |
| 100-125mg/m²             | 25  | 1 (4)             | 24 (96)   | 11.499  | 0.003  |
| 150mg/m²                 | 21  | 2 (9.5)           | 19 (90.5) | 0.069   | 1.000  |
| 180mg/m²                 | 3   | 2 (66.7)          | 1 (33.3)  | 0.069   | 1.000  |
(42.9%). Eighteen patients (36.7%) had a primary tumor site in the colon while fourteen patients (28.6%) had metastasis to the lung and liver. Most patients received irinotecan-based chemotherapy as a second line treatment (30 patients, 65.3%). Most participants had a good performance status represented by an ECOG score of 0 and 1.

**ABCC2 genotype frequencies**

Allele frequencies of **ABCC2** polymorphism (C>T, rs717620) was found at a rate of 18.37%. The wild type (C/C), heterozygous (C/T) and homozygous variants (T/T) were 65.3%, 32.7%, and 2.0%, respectively.

**SLCO1B1 genotype frequencies**

Allele frequencies of the **SLCO1B1** polymorphism (A>G, rs2306283) was found in 78.57%. The wild type (A/A), heterozygous variant (A/G) and homozygous variants (G/G) were found in 10.2%, 22.4%, and 67.3%, respectively.

The allele frequencies of SNPs in the **ABCC2** and **SLCO1B1** genes were tested with Hardy-Weinberg equilibrium. Significant differences were found between the observed and estimated frequencies of the **SLCO1B1** genotype ($\chi^2$ test=3.933 P=0.047), while no significant difference was found in the **ABCC2** genotype ($\chi^2$ test=0.059, P=0.807).

**Table 2. Association between Genetic Polymorphism and Clinical Benefit in Combined Genotype (ABCC2 and SLCO1B1*)**

| Allele SLCO1B1 | Allele ABCC2 | N   | Overall response* | $\chi^2$ value | P-value |
|----------------|--------------|-----|------------------|----------------|---------|
| AA+AG          | CC           | 10  | PR (30%) SD + PD (70%) | 7.440          | 0.059*  |
| CT + TT        | 6            | 6   | 6 (100%) PD (0%)    |                |         |
| GG             | CC           | 22  | 12 (54.5%) PD (45.5%) |                |         |
|                | CT + TT      | 11  | 6 (54.5%) PD (54.5%) |                |         |

**Table 3. Association between Genetic Polymorphism and Clinical Benefit in Combined Genotype (ABCC2 and SLCO1B1*1b)**

| Factor          | N   | PR (%) | SD + PD (%) | $\chi^2$ value | P-value |
|-----------------|-----|--------|-------------|----------------|---------|
| ABCC2 CC        | 32  | 4 (12.5) | 28 (87.5)  | 0.531          | 0.646   |
| CT,TT           | 17  | 1 (5.9)  | 16 (94.1)  |                |         |
| SLCO1B1 AA,AG   | 16  | 1 (6.3)  | 15 (93.7)  | 0.405          | 1.000   |
| GG              | 33  | 4 (12.1) | 29 (87.9)  |                |         |

ECOG, Eastern Cooperative Oncology Group. *Treatment response was an objective tumor response which was classified according to RECIST criteria.

**Patient characteristics and treatment responses**

Treatment response was an objective tumor response which was classified according to RECIST criteria. A responder was a patient who had a partial response (PR) or complete response (CR) and other patients who had progressive disease (PD) or stable disease (SD) were classified as non-responders. Complete responses were not seen in this study. Only 5 patients (10.2%) had a partial response. There were no statistically significant differences in the overall response rate according to gender, age, histology, primary tumor site, metastatic site, treatment line, and number of metastatic sites, previous treatments, performance status, alcohol status, or smoking status. Significant differences in treatment response were found only in each treatment regimen and irinotecan dose levels.

**The association of ABCC2 and SLCO1B1 polymorphisms on overall response**

Overall response rate among different genotypes of **ABCC2** are described in Table 2. Patients with the homozygous wild genotype (CC) had a higher of overall response (12.5% vs. 5.9%) when compared with

**Table 4. Association between Genetic Polymorphism and Anemia in Patients with the SLCO1B1 Polymorphism**

| Gene  | Anemia after cycle 2 | $\chi^2$ value | P-value |
|-------|----------------------|----------------|---------|
|       | Grade 0-2 | Grade 3-4 |       |
| SLC01B1 | AA       | 5 | 4 (80) | 1 (20) | 8.983 | 0.011* |
|       | GA       | 11 | 11 (100) | 0 (0) |     |         |
|       | GG       | 33 | 33 (100) | 0 (0) |     |         |
the CT and TT genotypes. However, there were no statistically significant differences.

For SLCO1B1, participants with the homozygous variant type (GG) of SLCO1B1*1b tended to have a higher response rate (12.1% and 6.3%) than patients with other genotypes but there was no statistical association between genetic polymorphisms and overall response rate.

**Association of ABCC2 and SLCO1B1 polymorphisms to clinical benefit**

Since complete response was not seen in this study, and only around 10% of participants had partial response to chemotherapy. Patients with stable diseases were considered as the part that received treatment benefit from chemotherapy given in term of longer progressive free duration while compared to those with disease progression. Therefore, we combined PR and SD in the same group of patients received clinical benefit from the treatment. When considering the combined genotypes of both genes, the results revealed that patients with the T/T, C/T genotypes of ABCC2 and the A/A, A/G genotypes of SLCO1B1 tended to have higher clinical benefit rates (P=0.059), as shown in Table 3.

In term of adverse events, the risk of severe anemia was higher in patients with the homozygous wild type (AA) of SLCO1B1 (20% and 0%) than in patients with other genotypes (P=0.011). The SLCO1B1 polymorphism also had an impact on non-hematologic toxicity as the rate of severe diarrhea was significantly higher in patients with the homozygous wild type (AA) (20% and 0%) than patients with other genotypes (P=0.011) as shown in Table 5.

**Discussion**

Association between UGT polymorphisms and irinotecan toxicities was well recognized since this drug recently approved and regularly used worldwide. Some authorities advise to perform genotypic testing prior to use this drug as mentioned earlier. However, Thai FDA does not provide any recommendation for genotypic testing, lower prevalence as approximately 8% and 12% of problematic genotypes (UGT1A1*6 and UGT1A1*28, respectively) might be the reason (Atasilp et al., 2016). Though, complexity of irinotecan metabolistic pathway, many of interesting drug metabolizing and transporting enzymes are still not well understood and need to clarify like ABCC2 and SLCO1B1 in our study.

In this study, the prevalence of ABCC2 and SLCO1B1 polymorphisms is reported and the impact of each genetic polymorphism on treatment response in Thai mCRC patients was investigated. The prevalence of ABCC2 of allele C→T rs717620 is found in 15-32% of the Caucasian population and 0% of the African population while a report from a study on Asians showed that allele T contributed 20.5% to advanced colorectal cancer in Japanese subjects (De Jong et al., 2007; Innocenti et al., 2009; Fujita et al., 2008). Our study reports the allele frequency T in Thai mCRC patients at 18.37% which is slightly lower than in the Japanese. The prevalence in SLCO1B1*1b of allele A→G rs2306283 was found to be 45% in the Caucasian population and 9% in Africans whereas a much higher rate, reaching 64.7-75% of allele frequency G, was found in Asians (Innocenti et al., 2009; Fujita et al., 2008; Huang et al., 2013). In Thais, this study found the allele frequency G of SLCO1B1*1b at 78.57% which is higher than previously reported.

Previous studies have explained the relationship between the ABCC2 polymorphism and overall chemotherapy response rate in Asians. Patients with the C/C genotype at -24 in ABCC2 showed an increased overall response rate to those with the C/T plus T/T genotype at 52.5% and 23.8%, respectively (P = 0.031) (Fujita et al., 2008). Similar to our study, patients with the homozygous wild genotype (CC) tended to have a higher rate of overall response (12.5% vs. 5.9%) than patients with the CT and TT genotypes though this was not statistically significant (P=0.646). In contrast, As Han (2007) reported in previous work significant tumor response rate in patients with T/T genotypes (P = 0.031) (Watanabe et al., 2009). Previous studies had reported an association between the SLCO1B1 polymorphism and tumor response. For example; As Huang et al., (2013) showed in previous work patients with GA/AA genotypes had significantly higher and more rapid tumor response rates than patients with the G/G genotype (P = 0.011) (Teft et al., 2015). On the other hand, our study found a contrary result, with a higher overall response rate in patients with the G/G genotype though this was not statistically significant. This result is in accordance with previous study reported patients with homozygous SLCO1B1 (388G/G) had significantly increased PFS compared with wild types (HR=1.60, 95% CI=1.04-2.46) (Teft et al., 2015).

As Di Martino et al., (2011) reported in previous work, 3 in 9 mCRC patients with the G/A genotype group suffered severe (grade ≥ 3) GI toxicity, while 14 of 17 patients in the other group had no GI toxicity (P = 0.027) which was consistent with our study which found a statistically significant difference in grade 3-4 severe diarrhea in patients with the AA genotype who underwent chemotherapy when compared to others.
Effects of ABCC2 and SLCO1B1 Polymorphisms

(P=0.011) (Teft et al., 2015). This study was the first to determine an association when considering the combined genotype of both genes and treatment response. Combining effects of ABCC2 and SLCO1B1*1b genotype might be one explanation for inter-individual variability on treatment response of irinotecan-based chemotherapy. Our results demonstrated the trend of association of at least one variant allele (T/T, C/T) of ABCC2 and at least one variant allele (A/A, A/G) of SLCO1B1*1b and the clinical benefit to irinotecan-treated patients (P=0.059). Several factors might impact the treatment response such as prior chemotherapy regimen, but except dose level of irinotecan and combined genotypic effect of ABCC2 and SLCO1B1*1b, there was no other significant association.

The strength of our study was its prospective design. However, when it come to the stratification that have been done in Table 3-5, the association between ABCC2 and SLCO1B1*1b polymorphisms, clinical benefit and severe toxicity in mCRC with irinotecan-based chemotherapy, the relatively small sample led to a small number of patients in each genotype group which accounted for the weak power of statistical results. Future studies with a larger sample size and more homogeneous treatment pattern should be conducted to elucidate the significance of these genetic polymorphisms on treatment response prior to concluding whether these genetic polymorphisms impact treatment outcomes.

In conclusion, this is the first study to determine the association between ABCC2 and SLCO1B1*1b polymorphisms with respect to treatment response of irinotecan-based chemotherapy in Thai mCRC patients. Our results indicated that ABCC2 and SLCO1B1 polymorphisms were not associated with any particular treatment response of irinotecan-based chemotherapy, while the combined effect of both genes tended towards clinical benefit. Therefore, polymorphisms of drug efflux and influx associated genes such as ABCC2 and SLCO1B1*1b might be important factors which can influence inter-individual variability on chemotherapy response in irinotecan-based chemotherapy for some cancer patients.

Conflict of interest statement

The authors declared no conflict of interest.

Acknowledgements

Research grant funds have been provided for this study by the 90th Anniversary Chulalongkorn University Fund (Ratchadapiseksomphot Endowment Fund).

References

Akiyama Y, Fujita K, Ishida H, et al (2012). Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab Pharmacokinet, 27, 325-35.

Atasilp C, Chansriwong P, Sirachainen E, et al (2016). Correlation of UGT1A1*28 and *6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacok, 31, 90-4.

Benson AB, Venook AP, Cedervist L, et al (2017). Colon cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 15, 370-98.

Colucci G, Giebbia V, Paolofti G, et al (2005). Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol, 23, 4866-75.

De Jong FA, Scott-Horton TJ, Kroetz DL, et al (2007). Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther, 81, 42-9.

Dmartino MT, Arbitrio M, Leone E, et al (2011). Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther, 12, 780-7.

Fuchs CS, Moore MR, Harker G, et al (2003). Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol, 21, 807-14.

Fujita K, Nagashima F, Yamamoto W, et al (2008). Association of ATP-binding cassette, sub- family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5- fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull, 31, 2137-42.

Haenisch S, Zimmermann U, Dazert E, et al (2007). Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J, 7, 56-65.

Han JY, Lim HS, Yoo YK, et al (2007). Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 110, 138-47.3

Hashim D, Boffetta P, La Vecchia C, et al (2016). The global decrease in cancer mortality: trends and disparities. Ann Oncol, 27, 926-33.

Huang L, Zhang T, Xie C, et al (2013). SLCO1B1 and SLC19A1 nucleotide polymorphisms. Drug Metab Dispos, 41, 780-7.

Huang L, Zhang T, Xie C, et al (2013). SLCO1B1 and SLC19A1 gene variants and irinotecan- induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One, 8, e77223.

Innocenti F, Kroetz DL, Schuetz E, et al (2009). Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol, 27, 2604-14.

Liu X, Chen D, Kuang Q, et al (2014). Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J, 14, 120-9.

Minami H, Sai K, Saeki M, et al (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom, 17, 497-504.

Nozawa T, Minami H, Sugiyama S, Tsuji A, Tami I (2005). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos, 33, 434-39.

Phiphaphatthamaarnphan K, Vilaiichone R (2016). Colorectal cancer in the central region of Thailand. Asian Pac J Cancer Prev, 17, 3647-50.

Teft WA, Welch S, Lenehan J, et al (2015). OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer, 112, 857-65.

Tournigand C, Andre T, Achille E, et al (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 15, 370-98.

DOI:10.22034/APJCP.2018.19.10.2757

Asian Pacific Journal of Cancer Prevention, Vol 19 2763
colorectal cancer: a randomized GERCOR study. *J Clin Oncol*, **22**, 229-37.

Watanabe H, Okada M, Kaji Y, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*, **45**, 228-47.

Zhou Q, Sparreboom A, Tan EH, et al (2005). Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. *Br J Clin Pharmacol*, **59**, 415-24.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.